1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Omnicell, Inc.
  6. Summary
    OMCL   US68213N1090

OMNICELL, INC.

(OMCL)
  Report
Delayed Nasdaq  -  04:00 2022-08-15 pm EDT
112.23 USD   +2.18%
08/09OMNICELL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/08Piper Sandler Adjusts Omnicell's Price Target to $150 From $162, Reiterates Overweight Rating
MT
08/05Berenberg Bank Adjusts Omnicell's Price Target to $152 From $162, Maintains Buy Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/09/2022 08/10/2022 08/11/2022 08/12/2022 08/15/2022 Date
105.24(c) 107.33(c) 109.18(c) 109.84(c) 112.23(c) Last
444 024 402 451 578 529 174 676 264 431 Volume
-3.86% +1.99% +1.72% +0.60% +2.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 396 M - -
Net income 2022 56,9 M - -
Net Debt 2022 120 M - -
P/E ratio 2022 84,1x
Yield 2022 -
Sales 2023 1 569 M - -
Net income 2023 96,7 M - -
Net Debt 2023 56,2 M - -
P/E ratio 2023 50,7x
Yield 2023 -
Capitalization 4 971 M 4 971 M -
EV / Sales 2022 3,65x
EV / Sales 2023 3,20x
Nbr of Employees 4 000
Free-Float 80,0%
More Financials
Company
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. The Company's point-of-care automation solutions are designed to improve... 
More about the company
Ratings of Omnicell, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about OMNICELL, INC.
08/09OMNICELL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
08/08Piper Sandler Adjusts Omnicell's Price Target to $150 From $162, Reiterates Overweight ..
MT
08/05Berenberg Bank Adjusts Omnicell's Price Target to $152 From $162, Maintains Buy Rating
MT
08/04OMNICELL : Q2 Earnings Snapshot
AQ
08/04TRANSCRIPT : Omnicell, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04OMNICELL : Announces Financial Results for Second Quarter 2022 - Form 8-K
PU
08/04OMNICELL, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
AQ
08/04Earnings Flash (OMCL) OMNICELL Posts Q2 EPS $0.84
MT
08/04Omnicell Announces Financial Results for Second Quarter 2022
BU
08/04Earnings Flash (OMCL) OMNICELL Reports Q2 Revenue $332M
MT
08/04Omnicell, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
08/04Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022
CI
07/27BTIG Adjusts Omnicell's Price Target to $175 from $190, Keeps Buy Rating
MT
07/15SVB Securities Initiates Coverage on Omnicell With Market Perform Rating, $124 Price Ta..
MT
07/11Omnicell to Release Second Quarter 2022 Financial Results on August 4, 2022
BU
More news
News in other languages on OMNICELL, INC.
08/04Earnings Flash (OMCL) OMNICELL annonce un chiffre d'affaires de 332 millions de dollars..
08/04Omnicell, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le ..
08/04Omnicell, Inc. fournit des prévisions de résultats pour le troisième trimestre et l'ann..
07/15USA-Les valeurs à suivre à Wall Street (actualisé)
05/24Omnicell, Inc. annonce des changements de direction
More news
Analyst Recommendations on OMNICELL, INC.
More recommendations
Chart OMNICELL, INC.
Duration : Period :
Omnicell, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMNICELL, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 112,23 $
Average target price 155,88 $
Spread / Average Target 38,9%
EPS Revisions
Managers and Directors
Randall A. Lipps Chairman
Peter J. Kuipers Chief Financial Officer & Executive Vice President
Giri Chodavarapu Chief Information Officer
Christine Mellon EVP, Chief Administrative & People Officer
Sara J. White Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMNICELL, INC.-37.80%4 971
VEEVA SYSTEMS INC.-10.38%35 454
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED-29.14%8 101
PRO MEDICUS LIMITED-16.72%3 907
SECTRA AB (PUBL)-11.89%3 344
EVOLENT HEALTH, INC.23.27%3 127